Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer

BACKGROUND: The presence of hypoxia is a poor prognostic factor in prostate cancer and the hypoxic tumor microenvironment promotes radioresistance. There is potential for drug radiotherapy combinations to improve the therapeutic ratio. We aimed to investigate whether hypoxia-associated genes could b...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Urol
Main Authors: Bibby, Becky A. S., Thiruthaneeswaran, Niluja, Yang, Lingjian, Pereira, Ronnie R., More, Elisabet, McArt, Darragh G., O’Reilly, Paul, Bristow, Robert G., Williams, Kaye J., Choudhury, Ananya, West, Catharine M. L.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8247203/
https://ncbi.nlm.nih.gov/pubmed/34210300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12894-021-00856-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados